FDA Expert Panel Backs Compounding of Six Peptides

An FDA advisory panel recently recommended adding six specific peptides to the list of substances allowed for pharmacy compounding. If the agency finalizes this move, pharmacists could legally produce these therapies for patient use. The substances under consideration include BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax. While the panel voted in favor of the expansion, this process faces significant regulatory hurdles and could take over a year to implement.

FDA scientific staff opposed the recommendation during the committee meetings. They cited a clear lack of safety and efficacy data, noting that these peptides have not undergone the rigorous clinical trials required for standard drug approval. Despite these concerns, many proponents argued that moving peptides into the regulated compounding space provides better oversight than the current gray market, where consumers frequently purchase products labeled as research chemicals.

Several committee members expressed discomfort with the decision, describing the lack of standardized data as a black box. Critics within the medical community worry that legalizing compounding for these substances undermines the established drug approval framework. They argue that patients deserve products with proven clinical utility rather than unverified substances.

Ultimately, the final decision rests with the FDA, which must now weigh the panel's advice against the agency's scientific findings. The FDA is expected to review thousands of public comments before issuing a formal rule. Furthermore, the agency has scheduled additional meetings for early 2027 to examine five more peptides, indicating that this debate over regulatory standards for emerging treatments is far from settled.